Fresh Frozen Plasma (FFP)

Mechanism of Action

Fresh frozen plasma is the fluid portion of a unit of whole blood frozen in a designated time frame, usually within 8 hours. Fresh frozen plasma contains all coagulation factors except platelets. Fresh frozen plasma contains fibrinogen (400 to 900 mg/unit), albumin, protein C, protein S, antithrombin, and tissue factor pathway inhibitors. It is free of erythrocytes and leukocytes.  Fresh frozen plasma corrects coagulopathy by replacing or supplying plasma proteins in patients deficient in or defective plasma proteins. A standard dose of 10 to 20 mL/kg (4 to 6 units in adults) raises factor levels by approximately 20%. Increasing roughly 10% of several factors is enough to bring about hemostasis. Also, fresh frozen plasma provides some volume resuscitation, as each unit contains approximately 250 mL.[4][5][6][7]

Administration

Fresh frozen plasma can only be administered intravenously. Fresh frozen plasma must be ABO compatible with the recipient’s red cells. Upon visual inspection, the fresh frozen plasma container and fluid should have no leakage, clots, or abnormal color. Fresh frozen plasma is stored at -30 Celsius. Before administration, fresh frozen plasma is thawed in a water bath at 30 to 37 Celsius over 20 to 30 minutes or in an FDA-cleared device as quickly as 2 to 3 minutes. Fresh frozen plasma should be administered immediately after thawing. If fresh frozen plasma is not given immediately after thawing, it should be stored at 1 to 6 Celsius. 

In some institutions, if the thawed fresh frozen plasma is not used in 24 hours, it is discarded. Some authorities advocated using thawed fresh frozen plasma for up to seven days. [8]Once thawed, the activity of clotting factors, particularly factor V and factor VIII, declines gradually. After the initial dosage, re-administration may be needed every 6 to 8 hours if there is ongoing bleeding due to the short half-life of factor VII; factor VII has a half-life of 2 to 6 hours.

Adverse Effects

The adverse effects of fresh frozen plasma administration are similar to those that pertain to whole blood and all blood components. They can be categorized into non-immunologic, immediate, and delayed immunologic complications. The acellularity of fresh frozen plasma spares certain disease transmission and blood immunogenicity: CMV and graft-versus-host disease cannot be transmitted by fresh frozen plasma as there are no viable leukocytes. Non-immunologic complications include the transmission of infectious agents, transfusion-associated circulatory overload (TACO), and metabolic complications like citrate toxicity. Infectious agents that are transmittable via fresh frozen plasma include HIV and hepatitis B and C. Screening and pathogen inactivation have reduced transmission rates of HIV to 1 in 7.8 million, hepatitis B virus to 1 in 153,000, and hepatitis C virus to 1 in 2.3 million.

TACO results from cardiogenic pulmonary edema and can occur after transfusion of excessive volumes or volumes at excessive rates. Immediate immunologic complications include hemolytic transfusion reaction, febrile non-hemolytic reaction, allergic reactions, anaphylactoid/anaphylactic reactions, and transfusion-related acute lung injury (TRALI). Hemolytic transfusion reaction occurs from anti-A and anti-B antibodies due to the failure of ABO matching. TRALI is the most common cause of transfusion-related death. TRALI is the acute onset of hypoxemia and non-cardiogenic pulmonary edema in the absence of other causes of acute lung injury or circulatory overload. TRALI occurs secondary to stimuli in blood components (white blood cell antibodies from donors and/or pro-inflammatory molecules accumulated in stored blood components) that trigger an inflammatory response, injuring the alveolar-capillary membrane and causing permeability pulmonary edema. Delayed immunologic complications include alloimmunization to plasma proteins.[9]

Contraindications

Fresh frozen plasma is contraindicated when coagulopathy can be corrected more effectively with specific therapy and when blood volume can be adequately replaced with other volume expanders. More specific treatments that merit consideration before fresh frozen plasma administration include vitamin K, cryoprecipitate antihemophilic factor, prothrombin complex concentrates, or specific coagulation factor concentrates like factor VII. Fresh frozen plasma should not be a volume expander without coagulation deficiencies and active bleeding. Fresh frozen plasma is contraindicated for reversing anticoagulation induced by heparin, direct thrombin inhibitors, or direct factor Xa inhibitors because these medications do not effectively reverse anticoagulation. Antidotes to reverse direct oral anticoagulants are better options.

Monitoring

The fresh frozen plasma therapy is monitored clinically with signs of bleeding and chemically with coagulation studies and fibrinogen levels. Each unit of fresh frozen plasma contains approximately 200 to 250 mL. Apheresis-derived units can contain as much as 400 to 600 mL. The 1 250 mL unit administration should raise the fibrinogen level by 5 to 10 mg/dl. The goal of therapy is a cessation of bleeding. The laboratory value goal is to correct the prothrombin time/activated partial thromboplastin time to less than 1.5 times normal.[10][11][12]

Toxicity

Citrate toxicity can occur with the administration of fresh frozen plasma. Most citrate in whole blood products is present in fresh frozen plasma and platelets, not packed red blood cells. Citrate chelates calcium and citrate intoxication causes hypocalcemia. Hypocalcemia signs and symptoms include hypotension, decreased pulse pressure, arrhythmias, mental status changes, and tetany. Treatment includes calcium administration.

Enhancing Healthcare Team Outcomes

There is a general assumption among healthcare workers that fresh frozen plasma is free of adverse effects and complications; nothing can be further from the truth. All interprofessional healthcare team members, including clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists, should know the indications for fresh frozen plasma administration and the monitoring process. The adverse effects of fresh frozen plasma are monitored like any other blood product administration. The patient’s vital signs (temperature, pulse, respiration, and blood pressure) are monitored before, during, and after administration. If a reaction is noted based on signs and symptomology, treatment is guided by the type of transfusion reaction. Usually, the administration of the product should immediately cease. Life-threatening reactions like TRALI and TACO may require aggressive respiratory support and often mechanical ventilation.

Proper administration and management of fresh frozen plasma require the efforts of an entire interprofessional team. Through proper knowledge and training, open information sharing and communication, and empowerment of each team member to contribute from their specialties, patients can achieve the best possible outcomes where fresh frozen plasma is indicated while having minimal adverse events.